Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-11 (Cancelled).

12(Currently amended). A composition for treating viral infections, said composition comprising ~~non-specifically~~ activated autologous lymphocytes effective against viral infections, said activated autologous lymphocytes being obtained by culturing autologous lymphocytes derived from a virally infected patient in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes, with the proviso that said virally-infected patient is not a cytomegalovirus-infected patient.

13(Currently amended). A method for preparing a composition for treating a viral infection, said method comprising deriving autologous lymphocytes from a virally infected patient and culturing said autologous lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and ~~non-specifically~~ activate *in vitro* said autologous lymphocytes which are effective against viral infections, with the proviso that said

virally-infected patient is not a cytomegalovirus-infected patient.

14(Currently amended). A method for treating a viral infection, said method comprising deriving autologous lymphocytes from a virally infected patient, culturing said autologous lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and ~~non-specifically~~ activate *in vitro* said autologous lymphocytes, and administering said ~~non-specifically~~ activated autologous lymphocytes which are effective against viral infections to said patient from which said autologous lymphocytes were derived.

15(Currently amended). The composition according to claim 12, wherein said activated autologous lymphocytes ~~cultivated~~ were proliferated and activated *in vitro* in said culture medium comprising ~~in vitro are suspended in~~ a buffer solution of physiological saline or phosphate buffer solution ~~to make a cell-suspended solution, and administered to said patient~~.

16(Currently amended). The composition according to claim 15, wherein said culture medium further comprises another [[a]] protein ~~is added to said cell-suspended solution~~.

17(Currently amended). The composition according to claim 16, wherein said another protein is human albumin.

18(Currently amended). The composition [[to]] of claim 12, wherein said culture medium further comprises ~~cytokine~~ cytokines.

19(Currently amended). The method according to claim 13, wherein said *in vitro* proliferated and activated autologous lymphocytes ~~cultivated *in vitro*~~ are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

20(Previously presented). The method according to claim 19, wherein a protein is added to said cell-suspended solution.

21(Previously presented). The method according to claim 20, wherein said protein is human albumin.

22(Previously presented). The method according to claim 13, wherein said culture medium further comprises cytokines.

23(Currently amended). The method according to claim 14, wherein said *in vitro* activated autologous lymphocytes ~~cultivated *in vitro*~~ are suspended in a buffer

solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

24(Previously presented). The method according to claim 23, wherein a protein is added to said cell-suspended solution.

25(Previously presented). The method according to claim 24, wherein said protein is human albumin.

26(Currently amended). The method according to claim 23, wherein said activated autologous lymphocytes having a cell concentration in the range of 1×10^4 parts/lit. to 1×10^8 parts/lit. are administered to same patient at a time.

27(Previously presented). The method according to claim 23, wherein said culture medium further comprises cytokines.

Claims 28-30 (Cancelled).

31(Previously presented). The method according to claim 13, wherein said viral infection is an Epstein-Barr viral infection.

32(Previously presented). The method according to claim 14, wherein said patient is virally infected,

immunodeficient or immunosuppressed due to an Epstein-Barr viral infection.

Claim 33 (Cancelled).

34(Previously presented). The method according to claim 13, wherein said viral infection is a herpes simplex viral infection.

35(Currently amended). The composition according to claim 12, wherein the activated autologous lymphocytes are T-lymphocytes.

36(Currently amended). The method according to claim 13, wherein the activated autologous lymphocytes are T-lymphocytes.

37(Currently amended). The method according to claim 14, wherein the activated autologous lymphocytes are T-lymphocytes.

38(Previously presented). The method according to claim 13, wherein the viral infection is a herpes group viral infection.

39(Previously presented). The method according to claim 14, wherein the viral infection is a herpes group viral infection.